Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study.

[1]  N. Keating,et al.  Challenges and Opportunities in Engaging Primary Care Providers in BRCA Testing: Results from the BFOR Study , 2021, Journal of General Internal Medicine.

[2]  B. Karlan,et al.  Comparison of up-front cash cards and checks as incentives for participation in a clinician survey: a study within a trial , 2020, BMC Medical Research Methodology.

[3]  S. Friedman,et al.  NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[4]  S. Young,et al.  Revised Common Rule Changes to the Consent Process and Consent Form , 2020, Ochsner Journal.

[5]  K. Offit,et al.  Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Aviad E. Raz,et al.  Population screening for BRCA1/BRCA2 founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral , 2019, Genetics in Medicine.

[7]  Katherine K. Kim,et al.  Are providers prepared for genomic medicine: interpretation of Direct-to-Consumer genetic testing (DTC-GT) results and genetic self-efficacy by medical professionals , 2019, BMC Health Services Research.

[8]  C. Wright,et al.  Direct-to-consumer genetic testing , 2019, BMJ.

[9]  J. Blum,et al.  Barriers to the utilization of genetic testing and genetic counseling in patients with suspected hereditary breast and ovarian cancers , 2019, Proceedings.

[10]  I. Jacobs,et al.  Attitude towards and factors affecting uptake of population‐based BRCA testing in the Ashkenazi Jewish population: a cohort study , 2019, BJOG : an international journal of obstetrics and gynaecology.

[11]  William R. Buckingham,et al.  Making Neighborhood-Disadvantage Metrics Accessible - The Neighborhood Atlas. , 2018, The New England journal of medicine.

[12]  H. LaDuca,et al.  False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care , 2018, Genetics in Medicine.

[13]  R. Bennett,et al.  Projecting the Supply and Demand for Certified Genetic Counselors: a Workforce Study , 2018, Journal of Genetic Counseling.

[14]  P. Kantoff,et al.  Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing , 2017, JAMA.

[15]  Antonis C. Antoniou,et al.  Cost‐effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry , 2017, American journal of obstetrics and gynecology.

[16]  Aviad E. Raz,et al.  Population screening for BRCA1/BRCA2 mutations: lessons from qualitative analysis of the screening experience , 2016, Genetics in Medicine.

[17]  N. Schreiber-Agus,et al.  Experiences from a pilot program bringing BRCA1/2 genetic screening to theUS Ashkenazi Jewish population , 2016, Genetics in Medicine.

[18]  C. Isaacs,et al.  Population-Based BRCA1/2 Testing in Ashkenazi Jews: Ready for Prime Time. , 2016, The Journal of the National Comprehensive Cancer Network.

[19]  A. Trepanier,et al.  Public Health Approaches and Barriers to Educating Providers about Hereditary Breast and Ovarian Cancer Syndrome , 2016, Healthcare.

[20]  Kenneth Offit,et al.  Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[21]  Stephanie A Cohen,et al.  Analysis of Advantages, Limitations, and Barriers of Genetic Counseling Service Delivery Models , 2016, Journal of Genetic Counseling.

[22]  M. King,et al.  Precision medicine meets public health: population screening for BRCA1 and BRCA2. , 2014, Journal of the National Cancer Institute.

[23]  J. Wardle,et al.  Population Testing for Cancer Predisposing BRCA1/BRCA2 Mutations in the Ashkenazi-Jewish Community: A Randomized Controlled Trial , 2014, Journal of the National Cancer Institute.

[24]  Christine Miller,et al.  Genetic counselor review of genetic test orders in a reference laboratory reduces unnecessary testing , 2014, American journal of medical genetics. Part A.

[25]  S. Narod,et al.  A comparison of the detection of BRCA mutation carriers through the provision of Jewish population-based genetic testing compared with clinic-based genetic testing , 2013, British Journal of Cancer.

[26]  S. Plevritis,et al.  A Simulation Model to Predict the Impact of Prophylactic Surgery and Screening on the Life Expectancy of BRCA1 and BRCA2 Mutation Carriers , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[27]  K. Hughes,et al.  Hereditary Breast and Ovarian Cancer and Other Hereditary Syndromes: Using Technology to Identify Carriers , 2012, Annals of Surgical Oncology.

[28]  Julie O. Culver,et al.  Genetics, genomics, and cancer risk assessment , 2011, CA: a cancer journal for clinicians.

[29]  Pascal Borry,et al.  Where are you going, where have you been: a recent history of the direct-to-consumer genetic testing market , 2010, Journal of Community Genetics.

[30]  S. Narod,et al.  Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[32]  Alfred A. Boyd,et al.  Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2 , 1996, Nature Genetics.

[33]  O. Olopade,et al.  USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan. , 2019, JAMA network open.

[34]  A. Berg.  U.S. Preventive Services Task Force , 2004 .

[35]  Anglian Breast Cancer Study Group.  Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases , 2000 .